𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885

✍ Scribed by Alex Y. Chang; Z. Nora Tu; George T. Bryan; John M. Kirkwood; Martin M. Oken; Donald L. Trump

Publisher
Springer US
Year
1994
Tongue
English
Weight
222 KB
Volume
12
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of constant-infusion fl
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma
✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 347 KB πŸ‘ 2 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p